×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BCDA – biocardia, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BCDA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/31
01:39 pm
bcda
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
Low
Report
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
3/31
08:00 am
bcda
Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years
High
Report
Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years
3/26
04:30 pm
bcda
BioCardia Reports 2024 Business Highlights and Financial Results
Medium
Report
BioCardia Reports 2024 Business Highlights and Financial Results
3/21
08:30 am
bcda
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
Medium
Report
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
3/10
09:15 am
bcda
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System
Low
Report
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System
2/27
07:08 pm
bcda
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions [Yahoo! Finance]
Medium
Report
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions [Yahoo! Finance]
2/27
09:15 am
bcda
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions
Low
Report
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions
2/22
11:52 pm
bcda
Creditors continue to hound Santa Fe real estate magnate [Yahoo! Finance]
High
Report
Creditors continue to hound Santa Fe real estate magnate [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/31
02:09 pm
bcda
Form 8-K BioCardia, Inc. For: Mar 31
Medium
Report
Form 8-K BioCardia, Inc. For: Mar 31
3/31
08:00 am
bcda
Form 8-K BioCardia, Inc. For: Mar 31
High
Report
Form 8-K BioCardia, Inc. For: Mar 31
3/26
05:20 pm
bcda
Form 8-K BioCardia, Inc. For: Mar 26
Medium
Report
Form 8-K BioCardia, Inc. For: Mar 26
3/26
05:18 pm
bcda
Form 10-K BioCardia, Inc. For: Dec 31
Medium
Report
Form 10-K BioCardia, Inc. For: Dec 31
3/10
09:15 am
bcda
Form 8-K BioCardia, Inc. For: Mar 10
Low
Report
Form 8-K BioCardia, Inc. For: Mar 10
3/7
08:30 am
bcda
Form 4 BioCardia, Inc. For: Mar 05 Filed by: STERTZER SIMON H
Low
Report
Form 4 BioCardia, Inc. For: Mar 05 Filed by: STERTZER SIMON H
3/5
08:30 am
bcda
Form 4 BioCardia, Inc. For: Mar 03 Filed by: STERTZER SIMON H
Low
Report
Form 4 BioCardia, Inc. For: Mar 03 Filed by: STERTZER SIMON H
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/28
BioCardia Awarded New U.S. Patent Covering Helix System for Local Biotherapeutic Delivery of Autologous and Allogenic Cells to the Heart
52.7%
10/1 BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures 15.2%
7/25 BioCardia Signs Exclusive Development Agreement With AstraZeneca 14.8%
1/8 BioCardia Announces New U.S. Patent Covering CardiAMP Cell Therapy and Issuance of Two Asian Patents Covering Radial Artery Approach for Cardiac Cell and Gene Therapy Delivery 13.9%
7/30 Form CERT BioCardia, Inc. 13.7%
4/1 BioCardia Inc (OTCMKTS: BCDA) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $9.00 price target on the stock. 9.9%
5/20 BioCardia Reports 2019 First Quarter Financial Results and Business Highlights 6.5%
3/12 BIOCARDIA ANNOUNCES TIMING FOR PRESPECIFIED DATA SAFETY MONITORING BOARD REPORT ON PIVOTAL CARDIAMP HEART FAILURE TRIAL 5.6%
10/8 BioCardia Receives CE Mark Renewal For Helix Biotherapeutic Delivery Catheter And Morph Guide Catheter Through May 2024 4.4%
2/17 BioCardia Inc (OTCMKTS: BCDA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 4.2%
10/1 BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures 15.2%
7/25 BioCardia Signs Exclusive Development Agreement With AstraZeneca 14.8%
1/8 BioCardia Announces New U.S. Patent Covering CardiAMP Cell Therapy and Issuance of Two Asian Patents Covering Radial Artery Approach for Cardiac Cell and Gene Therapy Delivery 13.9%
7/30 Form CERT BioCardia, Inc. 13.7%
4/1 BioCardia Inc (OTCMKTS: BCDA) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $9.00 price target on the stock. 9.9%
5/20 BioCardia Reports 2019 First Quarter Financial Results and Business Highlights 6.5%
3/12 BIOCARDIA ANNOUNCES TIMING FOR PRESPECIFIED DATA SAFETY MONITORING BOARD REPORT ON PIVOTAL CARDIAMP HEART FAILURE TRIAL 5.6%
10/8 BioCardia Receives CE Mark Renewal For Helix Biotherapeutic Delivery Catheter And Morph Guide Catheter Through May 2024 4.4%
2/17 BioCardia Inc (OTCMKTS: BCDA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 4.2%
TOP News Decliners
8/2
BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to Nasdaq
-64.3%
8/1 BioCardia Inc (OTCMKTS: BCDA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.6%
7/23 Form S-1/A BioCardia, Inc. -14.6%
10/2 BioCardia Announces the Appointment of Two New Board Members -11.3%
9/20 BioCardia Inc (OTCMKTS: BCDA) is now covered by analysts at Dawson James. They set a "buy" rating and a $24.00 price target on the stock. -7.7%
9/19 Biocardia Inc (NYSE: BCDA) had its "buy" rating re-affirmed by analysts at Dawson James. -6.0%
4/30 Biocardia Announces FDA-Recommended Modifications to Primary Endpoint for Cardiamp Cell Therapy Heart Failure Trial to Support Marketing Approval -5.0%
8/6 Form 4 BioCardia, Inc. For: Jul 05 Filed by: STERTZER SIMON H -4.9%
5/9 Form 8-K BioCardia, Inc. For: May 08 -4.3%
3/31 BIOCARDIA ANNOUNCES POSITIVE DSMB RECOMMENDATION TO CONTINUE PHASE III PIVOTAL CARDIAMP HEART FAILURE STUDY, AS PLANNED -3.1%
8/1 BioCardia Inc (OTCMKTS: BCDA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -17.6%
7/23 Form S-1/A BioCardia, Inc. -14.6%
10/2 BioCardia Announces the Appointment of Two New Board Members -11.3%
9/20 BioCardia Inc (OTCMKTS: BCDA) is now covered by analysts at Dawson James. They set a "buy" rating and a $24.00 price target on the stock. -7.7%
9/19 Biocardia Inc (NYSE: BCDA) had its "buy" rating re-affirmed by analysts at Dawson James. -6.0%
4/30 Biocardia Announces FDA-Recommended Modifications to Primary Endpoint for Cardiamp Cell Therapy Heart Failure Trial to Support Marketing Approval -5.0%
8/6 Form 4 BioCardia, Inc. For: Jul 05 Filed by: STERTZER SIMON H -4.9%
5/9 Form 8-K BioCardia, Inc. For: May 08 -4.3%
3/31 BIOCARDIA ANNOUNCES POSITIVE DSMB RECOMMENDATION TO CONTINUE PHASE III PIVOTAL CARDIAMP HEART FAILURE STUDY, AS PLANNED -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: